Related Experiment Video
Updated: Jul 23, 2026

Intubation-mediated Intratracheal (IMIT) Instillation: A Noninvasive, Lung-specific Delivery System
Published on: November 17, 2014
Nebulizer delivery of tobramycin to the lower respiratory tract
A Weber1, A Smith, J Williams-Warren
1Cystic Fibrosis Research Cener, Children's Hospital and Medical Center, Seattle, WA 98105.
Abstract:
We characterized a tobramycin aerosol generated by five nebulizers: Micron One, Pulmosonic, Pulmo-Aide, DeVilbiss Model 65, and UltraNeb 100 by particle size and drug concentration. The Micron One nebulizer did not produce a recoverable aerosol, while the Pulmosonic had a minimal output; therefore three machines were examined for their ability to deliver tobramycin to the lower respiratory tract of patients with cystic fibrosis (CF). The DeVilbiss 65 had the greatest output: with air as the carrier gas it produced an aerosol with > 60% of the particles having a mean mass aerodynamic diameter (MMAD) of > 5.5 microns. Using helox shifted the MMAD so that > 65% of the particles were < 5.5 microns. Increasing the power in the DeVilbiss 65 increased the output of particles > 9.2 microns, without a change in the particles < 3.3 microns. With air as the carrier gas the Pulmo-Aide and the UltraNeb 100 produced an aerosol with > 60% particles, < 3.3 microns MMAD. Using helox the UltraNeb 100 increased the amount of aerosol with a < 3.3 microns MMAD to 98%. Tobramycin delivery to the lower respiratory tract with the Pulmo-Aide and UltraNeb 100 was compared using air or helox by measuring sputum drug concentration. Pulmo-Aide failed to produce detectable tobramycin in sputum in 2 out of 9 patients with CF. With the UltraNeb 100, all patients had measurable sputum tobramycin immediately after administration (range, 16.2-3385 micrograms/g), but no statistically significant difference was found when using either compressed air, helox, or ambient air.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
The UltraNeb 100 nebulizer effectively delivered tobramycin to the lower respiratory tract in cystic fibrosis patients, with measurable sputum drug concentrations regardless of carrier gas. Other nebulizers showed varied particle sizes and drug delivery efficiency.
Area of Science:
- Pharmaceutical technology
- Respiratory medicine
- Medical device engineering
Background:
- Cystic fibrosis (CF) management often involves inhaled antibiotics like tobramycin.
- Optimizing aerosol delivery to the lower respiratory tract is crucial for treatment efficacy.
- Nebulizer performance varies, impacting drug deposition and therapeutic outcomes.
Purpose of the Study:
- To characterize tobramycin aerosol properties generated by different nebulizers.
- To evaluate the efficiency of tobramycin delivery to the lower respiratory tract in CF patients.
- To compare the impact of carrier gases (air vs. helox) on aerosol characteristics and drug delivery.
Main Methods:
- Five nebulizers (Micron One, Pulmosonic, Pulmo-Aide, DeVilbiss Model 65, UltraNeb 100) were tested for aerosol particle size (MMAD) and drug output.
- Tobramycin delivery was assessed by measuring sputum drug concentrations in CF patients.
- Carrier gases including compressed air, helox, and ambient air were utilized.
Main Results:
- Micron One and Pulmosonic nebulizers showed minimal or no recoverable aerosol output.
- DeVilbiss Model 65 produced larger particles (>5.5 microns MMAD) with air, shifting to smaller particles (<5.5 microns MMAD) with helox.
- UltraNeb 100 and Pulmo-Aide generated aerosols with >60% particles <3.3 microns MMAD with air; UltraNeb 100 achieved 98% with helox.
- UltraNeb 100 consistently resulted in measurable sputum tobramycin in CF patients, irrespective of carrier gas.
- Pulmo-Aide failed to produce detectable sputum tobramycin in some patients.
Conclusions:
- Nebulizer selection significantly impacts tobramycin aerosol characteristics and delivery efficiency.
- The UltraNeb 100 demonstrated reliable tobramycin delivery to the lower respiratory tract in CF patients.
- Carrier gas choice (air vs. helox) influenced particle size distribution but did not yield statistically significant differences in sputum drug concentration for the UltraNeb 100.
More Related Videos
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
05:45A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
Related Concept Videos
Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Inhaled Medications
Oxygen Delivering System II: Venturi Mask and Transtracheal Oxygen
Venturi Mask
The Venturi mask, named after the Venturi effect, is designed to deliver precise oxygen concentrations. It consists of a large tube with an oxygen inlet that narrows down, causing a pressure drop that pulls air in through adjustable side ports. The mask is a lightweight,...
Administering Oxygen by Nasal Cannula
Nasal Cannulas
A nasal cannula is a lightweight tube split into two prongs placed in the nostrils, connected...
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...